Renoprevention revisited-the impact of preemptive withdrawal of RAAS blockade prior to iodinated contrast exposure in older CKD patients: Results of a new meta-analysis

Cardiology (Switzerland)

Volumn 130, Issue 1, 2015, Pages 25-26

  Onuigbo, MacAulay Amechi Chukwukadibia ^a,b  

^a Mayo Clinic   (United States)

^b Mayo Clinic Health System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IODINATED CONTRAST MEDIUM; CONTRAST MEDIUM;

CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; EDITORIAL; HUMAN; KIDNEY FUNCTION; META ANALYSIS (TOPIC); PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; DRUG EFFECTS; META ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CONTRAST MEDIA; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 84927692230     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000369295     Document Type: Editorial

References (17)

1. Hou SH, Bushinsky DA, Wish JB, et al: Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983; 74: 243-248.
2. McCullough PA, Wolyn R, Rocher LL, et al: Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-375.
3. McCullough PA, Adam A, Becker CR, et al; CIN Consensus Working Panel: Epidemiology and prognostic implications of contrastinduced nephropathy. Am J Cardiol 2006; 98: 5K-13K.
4. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK: Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomized study. Indian Heart J 1999; 51: 521-526.
5. Li XM, Cong HL, Li TT, He LJ, Zhou YJ: Impact of benazepril on contrast-induced acute kidney injury for patients with mild to moderate renal insufficiency undergoing percutaneous coronary intervention. Chin Med J (Engl) 2011; 124: 2101-2106.
6. Toprak O, Cirit M, Bayata S, Yesil M, Aslan SL: The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography. Anadolu Kardiyol Derg 2003; 3: 98-103.
7. Kiski D, Stepper W, Brand E, Breithardt G, Reinecke H: Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post hoc analysis from the Dialysis-versus-Diuresis (DVD) trial. Nephrol Dial Transplant 2010; 25: 759-764.
8. Rim MY, Ro H, Kang WC, Kim AJ, Park H, Chang JH, Lee HH, Chung W, Jung JY: The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study. Am J Kidney Dis 2012; 60: 576-558.
9. Baris N, Ozpelit E, Dogan NB, Kangul H, Gul S, Akdeniz B, Guneri S: The effects of chronic usage of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on contrast-induced nephropathy in low-risk patients. Anadolu Kardiyol Derg 2013; 13: 245-250.
10. Komenda P, Zalunardo N, Burnett S, Love J, Buller C, Taylor P, Duncan J, Djurdjev O, Levin A: Conservative outpatient renoprotective protocol in patients with low GFR undergoing contrast angiography: a case series. Clin Exp Nephrol 2007; 11: 209-213.
11. Onuigbo MAC, Onuigbo NT: Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease A prospective 50-month Mayo Clinic study. Ren Fail 2008; 30: 67-72.
12. Jo SH, Lee JM, Park J, Kim HS: The impact of renin-angiotensin-aldosterone system blockade for contrast-induced nephropathy: a meta-analysis of 12 studies with 4, 493 patients. Cardiology 2015;130:4-14.
13. Onuigbo MAC: Reno-prevention vs. renoprotection: a critical re-appraisal of the evidence-base from the large RAAS blockade trials after ONTARGET-a call for more circumspection. QJM 2009; 102: 155-167.
14. Onuigbo MAC, Achebe NJ: Late Onset Renal Failure from Angiotensin Blockade (LORFFAB)-the results of a Mayo Clinic Health System Angiotensin Inhibition Withdrawal study: a clarion call for more preventative nephrology, also called renoprevention; in Onuigbo MAC (ed): ACE Inhibitors: Medical Uses, Mechanisms of Action, Potential Adverse Effects and Related Topic. New York, NOVA, 2013, vol 1, pp 75-90.
15. Tolwani A: Continuous renal-replacement therapy for acute kidney injury. N Engl J Med 2012; 367: 2505-2514.
16. Onuigbo MAC: Renoprevention: a new concept for reengineering nephrology care-an economic impact and patient outcome analysis of two hypothetical patient management paradigms in the CCU. Ren Fail 2013; 35: 23-28.
17. Onuigbo MAC, Agbasi N: 'Quadruple whammy'-a preventable newly described syndrome of post-operative AKI in CKD II and CKD III patients on combination 'Triple whammy' medications: a Mayo Clinic Health System, Eau Claire, Wisconsin experience. Niger J Clin Pract 2014; 17: 649-654.